IP Library Granted Patent US 10,392,355
Granted Patent B2
US 10,392,355 · App. 15/535,266 · Granted Aug 27, 2019

Processes for preparing oxathiazin-like compounds

Inventor: Rolf W. Pfirrmann (Weggis, CH)
Assignee: GEISTLICH PHARMA AG
C07D291/06A61P35/00C07D419/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,392,355
App. No.
15/535,266
Granted
Aug 27, 2019
Kind
B2
Abstract

Oxathiazin-like compounds, processes for making new oxathiazin-like compounds, compounds useful for making oxathiazin-like compounds, and their uses are disclosed. Processes of treating patients suffering from cancers, bacterial infections, fungal infections and/or viral infections by administering oxathiazin-like compounds are also disclosed. These compounds were found to have significantly longer half-life compared to taurolidine and taurultam.

Claims (27)

1. A process for preparing compound 2245, compound 2250, and/or compound 2255, comprising reacting compound 2244 as follows:

reacting compound 2245 as follows:

and/or reacting compound 2245 as follows:

2. The process of claim 1 , wherein compound 2244 is produced by reacting compound 2264 as follows:

wherein reaction C) comprises the following steps sequentially: dissolving compound 2264 in acetic ester and adding palladium/activated carbon to form a reaction mixture, autoclaving the reaction mixture, hydrogenating at about 50° C., cooling overnight, filtering and concentrating to dryness to obtain solid compound 2244;or

wherein reaction D) comprises the following steps sequentially: dissolving compound 2264 in acetic ester and adding palladium/activated carbon to form a reaction mixture, hydrogenating the mixture at room temperature and atmospheric pressure, removing the hydrogen, filtering, and drying to obtain solid compound 2444.

3. The process of claim 2 , wherein said reacting step A) further comprises boiling compound 2264 with concentrated HC1 and refluxing to form a reaction mixture, cooling the reaction mixture and separating an oil phase from an aqueous phase of the reaction mixture, concentrating the aqueous phase and cooling the oily residue to form crystals of 2244.

4. The process of claim 2 , wherein said reacting step A) further comprises boiling compound 2264 with concentrated HC1 and refluxing to form a reaction mixture, cooling the reaction mixture and separating an oil phase from an aqueous phase of the reaction mixture, dissolving the aqueous phase with methylene chloride, separating the methylene chloride, concentrating the aqueous phase and cooling to form an oil.

5. The process of claim 2 , wherein said reacting step A) further comprises boiling compound 2264 with concentrated HC1 and refluxing to form a reaction mixture, cooling the reaction mixture, adding dichloromethane to form an aqueous phase and an oily phase, evaporating an aqueous phase, seeding the oily phase with 2244 crystals, and obtaining crystals of 2244.

6. The process of claim 2 , wherein compound 2264 is produced by reacting compound 2261 as follows:

7. The process of claim 6 , wherein compound 2261 is produced by reacting compound 2260 as follows:

wherein DMF is dimethylformamide, or

8. The process of claim 1 , wherein a mixture of compound 2245 and compound 2250 is prepared by the following reaction:

9. The process of claim 1 , wherein compound 2250 is prepared by the following reaction:

10. The process of claim 1 , wherein compound 2250 is prepared by the following reaction:

11. The process of claim 1 , wherein a mixture of compound 2250 and compound 2255 is prepared by the following reaction:

12. A method of treating a subject having pancreatic cancer comprising administering compound 2250

and/or taurolidine in combination with gemcitabine to the subject.

13. A process for preparing compounds 2245 and 2250 comprising reacting compound 2244 as follows:

14. A process for preparing compound 2250 comprising reacting compound 2245 as follows:

15. A process for preparing compounds 2250 and 2255 comprising reacting compound 2245 as follows:

16. A process for preparing compound 2244 by reacting compound 2264 as follows:

17. The process of claim 16 , further comprising boiling compound 2264 with HC1 and refluxing to form a reaction mixture, cooling the reaction mixture and separating an oil phase from an aqueous phase of the reaction mixture.

18. A process for preparing compound 2264 by reacting compound 2261 as follows:

19. The process of claim 18 , further comprising producing compound 2261 by chlorinating compound 2260

20. A process of preparing compound 2250 using compound 2244 according to the following reaction:

21. A process of preparing compound 2250 using compound 2244 according to the following reaction:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2026
From: GEISTLICH PHARMA AG
To: PERSEVERE THERAPEUTICS INC.
Reel/Frame 075325/0017 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2017
From: PFIRRMANN, ROLF W.
To: GEISTLICH PHARMA AG
Reel/Frame 042685/0819 →
Continuity (2)
Provisional Application 62094580 · Dec 19, 2014
Related Publication 20180370932A1 · Dec 27, 2018
Cited By (1)
US 12,534,443